ROCE & ROE: The Capital Efficiency Metrics That Separate Wealth-Creators from Value-Destroyers — Titan Biotech’s 16.9% ROCE Decoded for Indian Investors

The Uncomfortable Truth About F&O Trading — And The Better Path

A landmark study by SEBI — India’s own market regulator — found that 9 out of 10 individual traders in Futures & Options lost money. Not just a little money. The average loss was significant enough to wipe out years of hard-earned savings. And yet, every day, millions of Indian investors continue to gamble on F&O contracts, hoping to get rich overnight.

Meanwhile, a quiet revolution is happening on the other side of Dalal Street. Patient, disciplined value investors — those who understand the fundamentals of quality businesses — have been compounding their wealth at extraordinary rates. One such business is Titan Biotech Ltd (BSE: 524717), a niche specialty chemicals and biological media company that has delivered over 5,000% returns in a decade while F&O traders watched their accounts bleed.

Today’s lesson focuses on two of the most powerful fundamental analysis metrics that would have helped you identify Titan Biotech as a quality compounder years before the crowd: Return on Capital Employed (ROCE) and Return on Equity (ROE). Master these, and you will see the stock market completely differently.

What is ROCE? The “Return on Capital Employed” Explained Simply

Imagine you run a small business. You invest ₹10 lakhs of your own money and borrow another ₹5 lakhs from the bank — total capital employed is ₹15 lakhs. At the end of the year, your business earns ₹2.5 lakhs in operating profit (EBIT — Earnings Before Interest and Tax).

Your ROCE = (EBIT ÷ Capital Employed) × 100 = (2.5 ÷ 15) × 100 = 16.7%

This means for every ₹100 deployed in the business (both your equity and borrowed money), the business generates ₹16.7 of operating profit. ROCE measures how efficiently a company uses ALL the capital at its disposal — both equity and debt.

What is ROE? Return on Equity — The Shareholder’s Lens

While ROCE measures returns on ALL capital, ROE focuses specifically on the returns generated on shareholders’ equity — the money that belongs to you as an owner.

The relationship between ROCE and ROE is crucial: when ROCE significantly exceeds the cost of debt, borrowing amplifies ROE (a good thing). But when ROCE is below the cost of debt, borrowing destroys value — which is exactly how overleveraged companies go bankrupt.

Why ROCE Above 15% is the Benchmark for Quality Businesses

The Nifty 50 index — India’s benchmark of the 50 largest companies — has historically delivered an average ROCE of approximately 12–14%. This is the “average” for India’s best large-cap companies.

A company consistently achieving ROCE above 15% is doing something special — it is generating returns that exceed what the best large-cap companies in India earn on average. Over time, such capital efficiency compounds into extraordinary wealth. Here is why:

The Compounding Power of Capital Efficiency: A company earning 20% ROCE reinvesting its profits will double its capital in approximately 3.6 years. A company earning only 10% ROCE will take approximately 7.2 years. Over a decade, the difference is not 2x but 4–6x in absolute wealth creation. This is why Warren Buffett obsesses over ROCE when evaluating businesses.

Titan Biotech as Case Study: ROCE of 16.9% and ROE of 15.0%

Now let’s apply this framework to Titan Biotech Ltd (BSE: 524717) — a 35-year-old specialty biological media company based in Bhiwadi, Rajasthan, with a current market cap of ₹2,082 crore.

Let’s unpack what these numbers tell us about Titan Biotech’s business quality:

1. ROCE of 16.9% — Above the Quality Threshold: Titan Biotech consistently earns ₹16.9 of operating profit for every ₹100 of total capital deployed in the business. This exceeds the Nifty 50 average of 12–14%, placing Titan Biotech in the top quartile of Indian businesses in terms of capital efficiency.

2. ROE of 15% — Shareholder Value Creation Confirmed: The 15% ROE means every ₹100 of equity capital generates ₹15 of net profit per year. With minimal debt (~0.02x D/E), this ROE is entirely organic — not artificially inflated by financial leverage. A company generating 15% ROE debt-free is fundamentally more valuable than one generating 20% ROE with heavy borrowings.

3. ROCE > ROE — The Debt-Free Signature: In Titan Biotech’s case, ROCE (16.9%) slightly exceeds ROE (15.0%). This relationship makes mathematical sense: when a company is virtually debt-free, ROCE and ROE converge. This is the signature of a clean, conservatively-managed balance sheet.

4. Operating Leverage Now Kicking In: Q3 FY26 showed revenue growth of 47.64% YoY, but profit growth was a stunning 107% YoY. This disproportionate profit growth vs. revenue growth is the classic signature of operating leverage — as revenues scale past the fixed cost base, margins expand dramatically. ROCE is likely to inch higher in FY26/27 as this plays out.

Peer Comparison: How Does Titan Biotech’s ROCE Stack Up?

Context is everything in investing. Let’s compare Titan Biotech’s capital efficiency with comparable businesses:

Note: Peer data based on publicly available information as of early 2026. Always verify from official sources before investing. This table is for educational comparison only.

The comparison reveals something remarkable: Titan Biotech stands alongside Divi’s Laboratories — one of India’s most celebrated quality compounders — in terms of capital efficiency and debt-free purity. The difference? Divi’s is a ₹1,00,000+ crore giant; Titan Biotech is a ₹2,082 crore nano-cap that still has enormous runway ahead of it. Divi’s Laboratories took decades to scale from where Titan Biotech is today. The quality blueprint is strikingly similar.

Why Titan Biotech’s ROCE Can Improve Further

Many investors look at ROCE as a static snapshot. Smart investors look at the trajectory — where is ROCE heading? For Titan Biotech, there are clear structural reasons to believe ROCE will improve over the next 3–5 years:

Operating Leverage Already Visible: As Q3 FY26 demonstrated (revenue +47.64%, profit +107%), Titan Biotech has crossed the threshold where incremental revenue flows disproportionately to the bottom line. Every additional rupee of revenue now generates a higher EBIT contribution, which directly feeds ROCE improvement.

Capacity Expansion Without Dilution: The company has historically expanded manufacturing through internally generated cash flows — zero equity dilution, zero excessive debt. Capital employed grows organically and productively, keeping ROCE stable or improving even as the business scales.

Export Growth Premium: Biological peptones and culture media for global pharmaceutical companies command premium pricing. As Titan Biotech’s export revenue grows, the higher-margin international business will lift the blended OPM and, in turn, lift ROCE.

₹145 Crore Reserves Built from Retained Earnings: The company has built reserves entirely from its own business over 30+ years. As these reserves get deployed in productive capacity expansion, ROCE benefits directly.

How to Use ROCE & ROE in Your Own Stock Analysis

Key Takeaways: What You Learned Today

SEBI Disclaimer: 9 out of 10 individual traders in the equity Futures & Options segment incurred net losses according to a SEBI study. F&O trading is essentially gambling. Focus on quality stock picking and long-term value investing instead.

Disclaimer: The author (Manish Goel) is a SEBI Registered Research Analyst (Registration No. INH100004775) and Multibagger Shares (Multibagger Securities Research & Advisory Pvt. Ltd.) is a SEBI Registered Investment Advisor (Registration No. INA100007736). This post is for educational purposes only and should not be construed as a buy/sell recommendation. Please do your own research and consult a qualified financial advisor before making investment decisions. Stock market investments are subject to market risks. Past performance is not indicative of future results.

mnshgoyal

See Full Bio